Like many cancers, mantle cell lymphoma can vary in how quickly it develops and its severity. As Szubanski's cancer has been described as "fast-moving" and is already stage 4, it appears that it ...

AstraZeneca’s Calquence has expanded its FDA approval to include first-line treatment of mantle cell lymphoma. The regulatory decision makes Calquence the first BTK inhibitor approved as an ...

SAN DIEGO — Mantle cell lymphoma patients who go into deep remission from a first therapy may not get any benefit from a follow-up transplant of their stem cells, according to a new study.

Mantle cell lymphoma (MCL) represents a relatively uncommon, heterogeneous lymphoma associated with limited overall survival. Targeting of the B-cell receptor pathway in relapsed disease with covalent ...

The ECHO trial's international scope, spanning 27 countries, underscores the global effort to improve treatment for this aggressive form of non-Hodgkin lymphoma.

Mantle cell lymphoma (MCL) is a rare form of cancer that affects B cells. B cells are a type of white blood in your immune system. MCL is part of a larger group of cancers called ...

Calquence ® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma. News release. AstraZeneca. October 3, 2024.

SAN DIEGO — Autologous hematopoietic stem cell transplantation did not benefit adults with mantle cell lymphoma in first complete remission after induction, according to randomized phase 3 data ...

December 19, 2007 (Atlanta) — Results obtained with an intensive immunotherapy regimen in mantle-cell lymphoma are so good that they suggest that a cure is in sight, said Christian Geisler, MD ...

Calquence ® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma. News release. AstraZeneca. January 17, 2025.

Mantle cell lymphoma is a rare, aggressive type of non-Hodgkin lymphoma arising from malignant B cells in the mantle zone of lymph nodes. It accounts for about 5% of lymphoma cases, is more common ...